Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fosamprenavir+ ritonavir+ methadone · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| fosamprenavir + ritonavir + methadone | DRUG | - |
Inclusion Criteria: * Subject is enrolled in a certified methadone maintenance program for at least 12 weeks prior to Period 1, Day 1. Subject is receiving methadone = 200mg QD that has remained unchanged for 30 days The subject is male, female and is between the age of 18 and 64 years of age. A ...
Fosamprenavir is an investigational small molecule being developed for the treatment of HIV infections, including HIV-1 infection in adults and pediatric subjects. It is studied in combination with other antiretroviral agents such as ritonavir, TRIZIVIR, or COMBIVIR. The drug is in Phase 3 clinical development for these indications.
Fosamprenavir is being developed by GSK plc, which trades under the ticker symbol GSK. The company is conducting clinical trials to evaluate the drug's safety and efficacy in treating HIV infections across various patient populations, including pediatric subjects aged 2 to 18 years and adults.
Fosamprenavir is a protease inhibitor that targets the HIV protease enzyme, which is essential for viral replication. By inhibiting this enzyme, the drug aims to prevent the maturation of infectious viral particles. It is being studied in combination with other antiretroviral medications for the treatment of HIV-1 infection.
Fosamprenavir is in Phase 3 clinical development for the treatment of HIV infections. It is an investigational drug and has not been approved by regulatory authorities. Clinical trials are ongoing to evaluate its safety and efficacy in various patient populations, including treatment-naive adults and pediatric subjects.
Fosamprenavir has been studied in several completed clinical trials, including NCT00040664 in pediatric subjects, NCT00043888 in adolescents and adults, NCT00094523 comparing it to other protease inhibitors, and NCT00450580 evaluating once-daily versus twice-daily dosing in treatment-naive adults. These trials enrolled a total of 753 participants.
Fosamprenavir is a distinct protease inhibitor used in combination with other antiretroviral agents. It is not the same as other HIV drugs, but it is often studied alongside medications like ritonavir, TRIZIVIR, and COMBIVIR to enhance its effectiveness. Its unique chemical structure and mechanism differentiate it from other protease inhibitors.